| Nov 14 |
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
|
| Nov 13 |
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
|
| Nov 13 |
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
|
| Nov 13 |
Q3 2024 Exagen Inc Earnings Call
|
| Nov 12 |
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Exagen GAAP EPS of -$0.28, revenue of $12.5M
|
| Nov 12 |
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
November 2024 Penny Stocks On US Exchanges To Consider
|
| Oct 29 |
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
|
